Horizon Therapeutics Stock Forecast, HZNP Price Prediction 2023 to 2028: Buy or Sell Horizon Therapeutics Plc Shares?

IQ Curator

Horizon Therapeutics Stock Forecast, HZNP Price Prediction 2023 to 2028: Buy or Sell Horizon Therapeutics Plc Shares?Photo byNational Cancer InstituteonUnsplash

Get expert insights into Horizon Therapeutics stock forecast and HZNP price prediction for 2023 to 2028. Make informed investment decisions on whether to buy or sell Horizon Therapeutics Plc shares. Discover the potential growth and performance of HZNP stock for long-term investment success.


Horizon Therapeutics, a distinguished player in the specialty pharmaceutical sector, has been making waves in the commercial landscape. Recently, the company grabbed attention with Amgen Inc.’s colossal bid of $27.8 billion, offering a substantial $116.50 per share. However, a twist in the tale emerged on May 16 when the Federal Trade Commission (FTC) took legal action to halt the acquisition.

As a result, the market sentiment turned sour, leading to a notable plunge in Horizon’s share price, which now stands at approximately $95 per share. Prior to this development, there were already doubts surrounding the acquisition, as Horizon’s shares had been trading at around $112. It is worth mentioning that Soros Fund Management demonstrated its confidence in Horizon Therapeutics by investing significantly, acquiring over 3.2 million shares valued at approximately $359.3 million.

This article delves into the recent events surrounding Horizon Therapeutics and provides a comprehensive analysis of the stock’s short-term and long-term forecast, offering valuable insights to investors.

Background of Horizon Therapeutics

Horizon Therapeutics is a well-established specialty pharmaceutical company with a focus on developing and commercializing innovative therapies for various medical conditions.

The company has a robust portfolio of products that address unmet medical needs in areas such as rare diseases, rheumatology, and ophthalmology. By concentrating on specialized pharmaceuticals, Horizon aims to provide valuable treatment options for patients with limited therapeutic alternatives.

Amgen’s Planned Acquisition

Amgen Inc., a prominent biotechnology company, expressed its intent to acquire Horizon Therapeutics in a deal worth $27.8 billion. The proposed acquisition involved Amgen offering $116.50 per share to Horizon’s shareholders.

This news generated considerable attention within the industry and among investors, as it indicated the potential for significant consolidation in the pharmaceutical sector. The anticipation of this acquisition impacted Horizon’s stock price.

Access the full article on IQ Curator and uncover a treasure trove of informative content waiting for you on our website.

This is original content from NewsBreak’s Creator Program. Join today to publish and share your own content.

Comments / 0

Published by

Unlock financial success with IQ Curator - your premier finance education website offering in-depth resources on personal finance, investing, budgeting, wealth management, retirement planning, and tax strategies. Master the art of money management and make informed financial decisions. Explore IQ Curator now for comprehensive finance knowledge and take control of your financial future.

Los Angeles, CA

More from IQ Curator

Comments / 0